. 2014 May 2;8:603–612. doi: 10.2147/PPA.S42789

Table 1.

Summary of agomelatine placebo-controlled and active comparator trials

Study dosage (mg/day)	N patients	HAM-D score baseline	HAM-D score at the end	P-value^*	CGI-S/CGI-I score	CGI-I/CGI-S score at the end	P-value^*
Loo et al⁴¹
Agomelatine 25 mg	135	27.4±2.7	12.8±8.2	P=0.034	4.7±0.7	2.8±1.4	P=0.42
Paroxetine 20 mg	144	27.3±3.4	13.1±8.4	P=0.030	4.9±0.7	2.8±1.5	P=0.51
Placebo	136	27.4±3.1	15.3±18.9		5.0±0.7	3.3±1.5
Kennedy and Emsley⁴²
Agomelatine 25–50 mg	106	26.5±2.8	14.1±7.7	P=0.026	4.8±0.7	3.2±1.3	P=0.017
Placebo	105	26.7±3.0	16.5±7.4		4.8±0.7	3.6±1.3
Olie and Kasper⁴³
Agomelatine 25–50 mg	116	27.4±2.7	13.9±7.7	P=0.002	4.9±0.7	3.2±0.3	P=0.017
Placebo	119	27.2±2.7	17.0±7.9		4.9±0.7	3.6±1.3
Lemoine et al⁴⁵
Agomelatine 25–50 mg	165	25.9±3.2	9.9±6.6	P=0.154	3.2±0.8	1.6±0.7	P=0.016
Venlafaxine 75–150 mg	167	26.0±3.3	11.0±7.4		3.6±0.9	1.6±0.8
Kennedy et al⁴⁶
Agomelatine 50 mg	137	27.9±4.1 (MADRS)	10.1±7.8 (MADRS)	P=0.751	4.4 (NR)	NR	NR
Venlafaxine ER 150 mg	139	27.9±4.6 (MADRS)	9.8±7.9 (MADRS)		4.5 (NR)	NR
Kasper and Hajak⁴⁷
Agomelatine 25–50 mg	150	26.1±2.8	10.3±7.0	P=0.031	4.7±0.7	2.5±1.1	P=0.043
Sertraline 50–150 mg	157	26.5±3.0	12.1±8.3		4.7±0.7	2.8±1.3
Goodwin et al⁵¹
24 weeks
Agomelatine 25–50 mg	165	6.1±2.6	7.5±7.0	P≤0.001	1.8±0.8	2.1±1.2	P=0.009
Placebo	174	6.0±2.7	10.6±8.4		1.8±0.7	2.6±1.5

Notes: Values are mean (±SD). P-value:

denotes difference in final score for agomelatine-treated patients versus final score for comparator patients.

Abbreviations: CGI-I, Clinical Global Impression Improvement Scale; CGI-S, Clinical Global Impression-Severity Scale; ER, extended release; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; NR, not reported; SD, standard deviation; N, number.